Trial Profile
A Pilot Study Evaluating the Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab in Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Pembrolizumab (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions
- 16 Jan 2023 Status changed from active, no longer recruiting to completed.
- 21 Sep 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Dec 2021.
- 02 Sep 2021 Results assessing safety and efficacy of combining pembrolizumab with standard of care doxorubicin for treatment of STS published in the Clinical Cancer Research